Clinical nephrology最新文献

Background: Peritoneal dialysis (PD) catheters can be inserted via open or laparoscopic techniques. Recent guidelines suggest advanced laparoscopic insertion for suitable patients, due to known catheter-related benefits, but surgical outcomes literature is lacking.

Materials and methods: We analyzed 11,731 PD catheter insertions from 2013 - 2018 in the National Surgical Quality Improvement Program database, including preoperative characteristics, operative details, and 30-day outcomes. Trends over time and factors associated with approach were assessed. Logistic regression examined the association between approach and postoperative mortality, complications, and length of stay.

Results: Laparoscopic PD catheter insertions increased from 76.1 to 87% of cases over the study period (p < 0.0001). Compared to laparoscopic procedures, open insertions were performed in older patients (58.8 vs. 58.1 years) with higher comorbidity. After adjustment, odds of 30-day mortality (OR 1.16, 95% CI 0.72 - 1.89), surgical site infections (OR 1.18, 95% CI 0.84 - 1.66), and other complications were similar between groups, although length of stay > 7 days remained modestly higher for open procedures (OR 1.43, 95% CI 1.03 - 1.99).

Conclusion: Use of laparoscopic PD catheter insertion has steadily increased from 2013 - 2018. After accounting for confounders, laparoscopic and open techniques had comparable early morbidity and mortality. These real-world data indicate increasing adoption of laparoscopic insertion as the predominant approach for PD access creation.

Background: Urinary magnesium plays an important role in the prevention of calcium oxalate stone formation, but the role of magnesium supplementation has yet to be clearly defined. We examined the urinary biochemistry of patients taking magnesium supplementation with meals versus while fasting.

Materials and methods: This was a single-institution, prospective, randomized controlled pilot study examining magnesium supplementation taken with meals versus while fasting in patients with a history of calcium oxalate stones and isolated hyperoxaluria. Patients were provided a controlled diet and randomized to take magnesium supplementation either fasting or with meals during a 7-day study period. A pre-intervention and post-intervention 24-hour urinalysis was completed for all patients.

Results: Eight patients were enrolled with 4 patients randomized to each arm of magnesium supplementation. Those taking magnesium supplementation with meals experienced a median decrease of 17.8 mg/d in urinary oxalate, increase of 33.6 mg/d in urinary magnesium, and increase of 134.8 mg/d in urinary citrate from the pre- to the post-intervention 24-hour urinalysis. Those taking supplementation while fasting experienced an average decrease of 8.5 mg/d in urinary oxalate, increase of 21.8 mg/d in urinary magnesium, and increase of 116.6 mg/d of urinary citrate.

Conclusion: Patients with a prior history of calcium oxalate stone formation and isolated hyperoxaluria who took magnesium supplementation with meals were found to have a more substantial improvement in urinary parameters on 24-hour urinalysis compared to those who took magnesium supplementation while fasting. Magnesium supplementation should be taken with meals if prescribed for the prevention of recurrent calcium oxalate nephrolithiasis.

Regarding the article by Fredrik Barth Brekke, Nanna von der Lippe, Ine Røed, Helga Gudmundsdottir, Martin Braaten, Espen Nordheim. Hyperbaric oxygen treatment in addition to conventional multidisciplinary care in patients with calciphylaxis. Clin Nephrol. 2025; 103: 1-4. doi: 10.5414/ CN111423, the authors would like to apologize for the error in Table 1 of page 2. Five patients were misclassified as CKD5 patients when established in dialysis. The correct number of patients in different CKD5 stage is corrected and marked in bold in revised Table 1 presented below. The same information is referred in the text in the following sentence: Ten patients (40%) had end-stage renal disease in need of renal replacement therapy at diagnosis (…). The correct number is 15 (60%). We have recalculated the statistics to make sure this has not affected the rest of our results including page 3 "there was no survival difference between patients on renal replacement therapy and patients not treated with renal replacement therapy" which is still correct. We are very sorry for any inconvenience due to these unfortunate errors.

Objective: The aim of this study was to determine the prevalence of renal insufficiency in patients with lung cancer and factors associated with its development.

Materials and methods: All patients at the First Affiliated Hospital of Guangzhou Medical University from January 1 to December 31, 2016 who had lung cancer were included in this study. Baseline characteristics, including age, sex, clinical features, estimated glomerular filtration rate (eGFR), echocardiographic findings, electrocardiogram results, and biochemical indicators were collected retrospectively. eGFR was divided into three categories: ≥ 60, 45 - 59, and < 45 mL/min/1.73m². Renal insufficiency was defined as eGFR < 60 mL/min/1.73m². The prevalence of co-occurring lung cancer and renal insufficiency as well as factors associated with it were also studied.

Results: A total of 140 patients with a lung cancer diagnosis confirmed by pathologic examination were included. The prevalence of eGFR ≥ 60, 45 - 59, and < 45 mL/min/1.73m² categories was 77.14%, 12.14%, and 10.71%, respectively. The lung cancer subtypes were adenocarcinoma (102 cases (72.86%)), squamous cell carcinoma (23 cases (16.43%)), and small cell carcinoma (15 cases (10.71%)). Logistic regression analysis showed that age (odds ratio (OR), 5.522; 95% CI, 2.712 - 11.243; p < 0.001), proteinuria (OR, 4.832; 95% CI, 1.518 - 15.383; p = 0.008), and thyroid-specific transcription factor-1 (TTF-1) positivity (OR, 5.730; 95% CI, 1.509 - 21.754; p = 0.010) were independently associated with eGFR category < 60 mL/min/1.73m². Age (OR, 2.372; 95% CI, 1.331 - 4.228; p = 0.003) and TTF-1 positivity (OR, 12.791; 95% CI, 3.394 - 49.575; p < 0.001) were independently associated with eGFR category 45 - 59 mL/min/1.73m2. Finally, age (OR, 4.083; 95% CI, 1.979 - 8.426; p < 0.001), low albumin (OR, 9.05; 95% CI, 1.335 - 61.349; p = 0.024), and hyperuricemia (OR, 4.974; 95% CI, 1.22 - 20.282; p = 0.025) were independently associated with eGFR category < 45 mL/min/1.73m².

Conclusion: Renal function is an important parameter to monitor in patients undergoing lung cancer treatment. The patient's age and presence of proteinuria, low albumin, hyperuricemia, and TTF-1 positivity in lung cancer are all independently associated with renal insufficiency in these patients. To ensure safe recovery and discharge after lung cancer treatment, factors associated with renal insufficiency should be recognized during treatment. Large-scale multicenter trials are warranted for further validation of these findings.

Background: Cushing's syndrome is a rare cause of secondary hypertension. There are several mechanisms reported as contributing factors for blood pressure elevation in hypercortisolism patients. This case highlights the central role of mineralocorticoid receptors' activation by the excess cortisol in the development of hypertension.

Case presentation: A 45-year-old male presented with several months of cushingoid features and refractory hypertension on maximum doses of five antihypertensive drugs, not including a mineralocorticoid receptor blocker. Workup for other causes of secondary hypertension revealed sleep apnea but was otherwise negative. Further evaluation revealed a carcinoid lung tumor as the cause of Cushing's syndrome with its ectopic production of adrenocorticotropic hormone (ACTH). Prior to the resection of this tumor, the addition of eplerenone, a mineralocorticoid receptor blocker, resulted in significant improvement in blood pressure within 4 weeks, highlighting that cortisol activation of mineralocorticoid receptors is one of the main mechanisms of hypertension in this patient with hypercortisolism.

Conclusion: In hypercortisolism patients, some excess cortisol escapes deactivation by the 11β-hydroxysteroid dehydrogenase 2 enzyme in the kidney and directly activates mineralocorticoid receptors. Recent literature suggests that specific patient populations have subtle elevations in cortisol levels, and cortisol's effect on end-organ damage follows a spectrum from high-normal cortisol to overt hypercortisolism. Other data suggest a decline in 11β-hydroxysteroid dehydrogenase 2 enzyme activity with age. Additional research is needed to further define the role of cortisol-mineralocorticoid receptor interaction in hypertension among patients without overt hypercortisolism but with high-normal cortisol or low 11β-hydroxysteroid dehydrogenase 2 enzymatic activity.

Background: Acute kidney injury (AKI) is a clinically complex syndrome with a high incidence and mortality rate in the intensive care unit (ICU). Early identification of high-risk patients and timely intervention are crucial.

Objective: A local database was used to construct a model that predicts the incidence of AKI in ICU patients within 48 hours.

Materials and methods: We conducted a study involving 9,628 critically ill patients at Zhejiang Provincial People's Hospital and divided the cohort into derivation and validation groups. We collected and analyzed demographic data, vital signs, laboratory tests, medications, clinical interventions, and other information for all patients, resulting in a total of 232 variables. Six different machine learning algorithms were employed to construct models, and the optimal model was selected and validated.

Results: A total of 2,441 patients were included, of whom 1,138 (46.62%) met the AKI criteria. A model was derived that included 16 variables such as albumin transfusion, fluid balance, diastolic blood pressure (DBP), partial pressure of oxygen (PO₂), blood glucose (GLU), platelet (PLT), baseline serum creatinine (bSCr), serum sodium, age, epinephrine, proton pump inhibitor (PPI), intra-abdominal infection, anemia, diabetes, glycerin fructose, and nutritional pathway. The area under the receiver operating characteristic curve (AUC) was 0.822. Subgroup analysis revealed the impact of blood pressure fluctuations on AKI. Additionally, the study demonstrated a bidirectional effect of albumin and fluid balance on AKI.

Conclusion: This model is highly accurate and may facilitate the early diagnosis of and interventions for AKI.

Background: Patients receiving maintenance hemodialysis (MHD) are at increased risk of osteoporosis. The effects of bilirubin on bone metabolism vary among different disease populations. However, the relationship between total bilirubin (TBIL) and bone metabolism in MHD has not been investigated yet.

Materials and methods: This cross-sectional study included 122 MHD patients aged ≥ 18 years who underwent regular hemodialysis at the Blood Purification Center of Aerospace Central Hospital from April 2021 to April 2023. Blood sampling and bone mineral density (BMD) examinations were conducted. Multivariate linear regression, restricted cubic spline and subgroup analyses were performed to evaluate the association between TBIL and BMD.

Results: TBIL (correlation coefficient: 1.7 (0.17, 3.25); p = 0.04) was independently associated with BMD in the multivariate linear regression analysis. The results showed that BMD was nonlinearly related to TBIL in MHD patients, exhibiting a J shaped curve (p = 0.035). When plasma TBIL level < 0.64 mg/dL, there is an average increase of 5.3 (95% CI: 2.0 - 8.7; p = 0.002) g/cm² in BMD for every 1-unit increase in plasma TBIL level. The association between TBIL and BMD was not significant when the plasma TBIL level was ≥ 0.64 mg/dL.

Conclusion: The relationship between TBIL and BMD in MHD patients is J-shaped, with an inflection point of 0.64 mg/dL.

Introduction: Lung cancer ranks among the foremost causes of mortality associated with cancer. Ensartinib is a highly effective oral anaplastic lymphoma kinase (ALK) inhibitor utilized in the treatment of ALK-positive lung adenocarcinoma. This report presents a case of acute renal failure attributed to the administration of ensartinib. This is the first case report documenting the nephrotoxic effects of ensartinib, specifically manifesting as acute tubulointerstitial nephritis (ATIN) and IgA nephropathy.

Case presentation: This report details the case of a 52-year-old man diagnosed with ALK-positive lung adenocarcinoma. The patient was initially treated with crizotinib for a duration exceeding 6 months; however, he was subsequently transitioned to ensartinib due to disease progression characterized by the development of brain metastases. Within 3 months of initiating treatment with ensartinib, the patient experienced acute kidney failure. The renal failure was attributed to ATIN and IgA nephropathy, which were considered manifestations of renal toxicity associated with ensartinib.

Conclusion: This case underscores the uncommon adverse effect of ALK-targeting therapy, specifically regarding acute renal failure induced by ensartinib. We recommend conducting a renal biopsy to ascertain the presence of drug-induced nephrotoxicity. An accurate diagnosis and timely intervention can prevent the deterioration of renal function.